Effectiveness of immune therapy combined with chemotherapy on the immune function and recurrence rate of cervical cancer

Experimental and Therapeutic Medicine

Volumn 9, Issue 3, 2015, Pages 1063-1067

  Chen, Bin ^a   Liu, Lifen ^b   Xu, Haiyan ^a   Yang, Yijin ^a   Zhang, Ling ^a   Zhang, Fengchun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Cervical cancer; Cisplatin; Dendritic cell cytokine induced killer cell; Immune function; Recurrence rate

Indexed keywords

CD16 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CISPLATIN; GRANZYME B; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PERFORIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; UTERINE CERVIX CANCER;

EID: 84922051749     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2217     Document Type: Article

References (23)

1. Bynum SA, Brandt HM, Sharpe PA, Williams MS and Kerr JC: Working to close the gap: identifying predictors of HPV vaccine uptake among young African American women. J Health Care Poor Underserved 22: 549-561, 2011.
2. Wang XC and Wu MY: Progress on DC-CIK-based adoptive cellular immunotherapy for uterine cervical neoplasm. Guangdong Yao Xue Yuan Xue Bao 29: 575-579, 2013 (In Chinese).
3. Tewari KS and Monk BJ: New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy. Clin Cancer Res 20: 5349-5358, 2014.
4. Wang FS, Liu MX, Zhang B, et al: Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 8: 464-468, 2002.
5. Itsumi M and Tatsugami K: Immunotherapy for renal cell carcinoma. Clin Dev Immunol 2010: 284581, 2010.
6. Kim HM, Lim J, Kang JS, et al: Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model. Int Immunopharmacol 9: 375-380, 2009.
7. Hontscha C, Borck Y, Zhou H, Messmer D and Schmidt-Wolf IG: Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137: 305-310, 2011.
8. Palucka K and Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12: 265-277, 2012.
9. Bhargava A, Bunkar N, Khare NK, Mishra D and Mishra PK: Nanoengineered strategies to optimize dendritic cells for gastrointestinal tumor immunotherapy: from biology to translational medicine. Nanomedicine (Lond) 9: 2187-2202, 2014.
10. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
11. Kastritis E, Bamias A, Bozas G, et al: The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy. Gynecol Oncol 104: 372-376, 2007.
12. Motz GT and Coukos G: Deciphering and reversing tumor immune suppression. Immunity 39: 61-73, 2013.
13. Lindau D, Gielen P, Kroesen M, Wesseling P and Adema GJ: The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138: 105-115, 2013.
14. Hasan UA, Bates E, Takeshita F, et al: TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178: 3186-3197, 2007.
15. Wang X, Yu W, Li H, Yu J, Zhang X, Ren X and Cao S: Can the dual-functional capability of CIK cells be used to improve antitumor effects? Cell Immunol 287: 18-22, 2014.
16. Wang QJ, Wang H, Pan K, et al: Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK) and semi-allogeneic DC-CIK. Chin J Cancer 29: 641-648, 2010
17. Zheng YW, Li RM, Zhang XW and Ren XB: Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest 31: 197-205, 2013.
18. Ren J, Di L, Song G, Yu J, et al: Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clin Transl Oncol 15: 780-788, 2013.
19. Yang HZ, Shi N, Li LN, Kang H and Yang LN: Clinical research of interventional treatment combined with CIK in patients with uterine cervix cancer. Haerbin Yi Ke Da Xue Xue Bao 44: 263-266, 2010 (In Chinese).
20. Zhu YH, Liu JQ, Cao H, et al: Clinical efficiency of radiotherapy combined with self-immune cell therapy for cervical carcinoma. Zhongguo Zhong Liu Sheng Wu Zhi Liao Za Zhi 19: 421-427, 2012 (In Chinese).
21. Laurin D, Marin V, Biagi E, et al: Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells. J Biomed Biotechnol 2010: 234540, 2010.
22. Hackstein H and Thomson AW: Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 4: 24-34, 2004.
23. Yang L, Ren B, Li H, Yu J, Cao S, Hao X and Ren X: Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 62: 65-73, 2013.